As the April showers turn to May flowers, take a moment to check out some of the research ethics and oversight news that has been making headlines this month.
It’s back to school and back to work! Get into the swing of things by catching up on the latest news in the research ethics world (which never goes on vacation)!
Aveo Reeling after FDA's Rejection of Kidney Cancer Drug: Aveo Pharmaceuticals spent seven years and $300 million developing tivozanib, a kidney cancer drug, which was recently rejected by the [...] Read more
by Maeve Luthin, JD, Professional Development Manager
In June’s Association for Molecular Pathology v. Myriad Genetics, Inc. (Myriad) decision, the Supreme Court determined that human genes fall within the “laws of nature” exception to patentable material. This decision invalidated Myriad’s exclusive claim to BRCA 1 and BRCA 2 tests that can be used in determining a woman’s risk in contracting breast and ovarian cancer. However, Myriad wasn’[...] Read more